Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of products and procedures to transform the treatment of glaucoma. The Company has pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to change the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent Trabecular Micro-Bypass Stent, its first MIGS device. The Company is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression.

Company Growth (employees)
Laguna Hills, US
Size (employees)
264 (est)+5%
Glaukos was founded in 1998 and is headquartered in Laguna Hills, US

Key People/Management at Glaukos

Thomas Burns

Thomas Burns

President, Chief Executive Officer
Chris Calcaterra

Chris Calcaterra

Chief Operating Officer
Joseph Gilliam

Joseph Gilliam

Chief Financial Officer, Senior Vice President, Corporate Development
Robert Davis

Robert Davis

Senior Vice President, General Counsel
Michele Allegretto

Michele Allegretto

Vice President, Human Resources
Sheree Aronson

Sheree Aronson

Vice President, Investor Relations & Corporate Marketing
David Haffner

David Haffner

Senior Vice President, New Technologies

Glaukos Office Locations

Glaukos has offices in Laguna Hills, Madrid, Chicago, Barcelona and in 15 other locations
Laguna Hills, US (HQ)
26051 Merit Circle
Show all (19)

Glaukos Financials and Metrics

Glaukos Financials


Market capitalization (22-Dec-2017)

997.1 m
Glaukos's current market capitalization is $997.1 m.
Show all financial metrics

Glaukos Market Value History

Glaukos's Web-traffic and Trends

Glaukos Online and Social Media Presence

Glaukos Company Life and Culture

You may also be interested in